Why Are Journey Medical Shares Trading Higher Today

Journey Medical Corporation DERM announced topline data from the Phase 1 clinical trial assessing the impact of DFD-29 on the microbial flora of healthy adults. 

The clinical trial also assessed the safety and tolerability of the treatment. DFD-29 is being developed for papulopustular rosacea in collaboration with Dr. Reddy's Laboratories Ltd RDY.

Rosacea is a chronic, relapsing, inflammatory skin condition commonly presenting with symptoms such as deep facial redness, acne-like inflammatory lesions, and spider veins. 

The study achieved all primary objectives and noted no significant safety issues. 

Treatment with DFD-29 for 16 weeks did not significantly impact the normal microbial flora and did not induce significant bacterial resistance. 

Additionally, treatment with DFD-29 did not cause a significant proliferation of opportunistic organisms. The results indicate that DFD-29 can be safely used for up to 16 weeks with no significant risk of microbiota suppression or development of resistance. 

The company anticipates topline data from the Phase 3 trials in June, with a New Drug Application filing subsequently expected in the second half of 2023.

Price Action: DERM shares are up 8.98% at $1.82 on the last check Tuesday.